These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2855291)

  • 1. [Effect of antithrombin III on the binding of heparin and its low molecular weight fraction CY 216 with endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1988; 19(3-4):143-9. PubMed ID: 2855291
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetics of binding of I-125-labeled heparin and its low-molecular-weight fraction CY 222 to the endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1987; 18(1-2):35-41. PubMed ID: 2829494
    [No Abstract]   [Full Text] [Related]  

  • 3. [Binding of technetium 99m-labeled heparin and its low molecular weight fractions CY 216 and CY 222 to human endothelium in vitro].
    Psuja P
    Pol Tyg Lek; 1987 Jul; 42(30):903-6. PubMed ID: 2823236
    [No Abstract]   [Full Text] [Related]  

  • 4. Affinity of binding of radiolabeled (125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture.
    Psuja P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):429-36. PubMed ID: 2444518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III.
    Baruch D; Ajzenberg N; Denis C; Legendre P; Lormeau JC; Meyer D
    Thromb Haemost; 1994 Jan; 71(1):141-6. PubMed ID: 8165633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells.
    Reantragoon S; Arrigo LM; Seoud MM; Dweck HS; Rosenfeld L
    Arch Biochem Biophys; 1994 Nov; 314(2):315-22. PubMed ID: 7979371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and activity of heparin and its fragments: an overview.
    Choay J
    Semin Thromb Hemost; 1989 Oct; 15(4):359-64. PubMed ID: 2479102
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombogenicity of the injured vessel wall--role of antithrombin and heparin.
    Frebelius S; Hedin U; Swedenborg J
    Thromb Haemost; 1994 Jan; 71(1):147-53. PubMed ID: 8165634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first component of the human complement system recognizes the active fraction of heparin.
    Calabrese GC; Recondo MM; Fernández de Recondo ME; Recondo EF
    Cell Mol Biol (Noisy-le-grand); 1997 Mar; 43(2):237-42. PubMed ID: 9130607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.
    Bârzu T; Molho P; Tobelem G; Petitou M; Caen JP
    Nouv Rev Fr Hematol (1978); 1984; 26(4):243-7. PubMed ID: 6473094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight.
    Khorana AA; Sahni A; Altland OD; Francis CW
    Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2110-5. PubMed ID: 12920044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemistry of heparin and low molecular weight heparin.
    Nielsen JI; Ostergaard P
    Acta Chir Scand Suppl; 1988; 543():52-6. PubMed ID: 2847458
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.
    Pimenta DC; Nantes IL; de Souza ES; Le Bonniec B; Ito AS; Tersariol IL; Oliveira V; Juliano MA; Juliano L
    Biochem J; 2002 Sep; 366(Pt 2):435-46. PubMed ID: 12000310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III, a serpin family protease inhibitor, is a major heparin binding protein in porcine aqueous humor.
    Rao PV; Allingham RR; Herndon LW; Epstein DL
    Biochem Biophys Res Commun; 2000 May; 272(1):1-5. PubMed ID: 10872794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding and endocytosis of heparin by human endothelial cells in culture.
    Bârzu T; Molho P; Tobelem G; Petitou M; Caen J
    Biochim Biophys Acta; 1985 May; 845(2):196-203. PubMed ID: 3995089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
    Sakuragawa N; Niiya K; Takahashi K; Hayashi T; Oguma Y; Saitoh S
    Rinsho Byori; 1993 May; 41(5):492-505. PubMed ID: 8350512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.